- Theratechnologies Inc. (NASDAQ: THTX) held its virtual annual meeting of shareholders on May 29, 2025, electing eight directors to the Board.
- Shareholders approved KPMG LLP as auditors and an omnibus long-term incentive plan for directors, executives, and employees.
- Joseph Arena received the highest approval rate among directors, with 84.03% voting in his favor.
Theratechnologies Inc. (NASDAQ: THTX), a biopharmaceutical company, successfully conducted its annual shareholder meeting virtually on May 29, 2025. Shareholders elected eight directors to the company's Board for a one-year term, with approval rates ranging from 77.98% to 84.03%. Joseph Arena emerged with the highest level of shareholder support, securing 84.03% of the votes, while Dawn Svoronos received 77.98% approval.
During the meeting, shareholders also sanctioned the appointment of KPMG LLP as the company's auditors for the current fiscal year. Furthermore, an omnibus long-term incentive plan designed to benefit the directors, executive officers, and employees of Theratechnologies and its subsidiaries was approved.
Theratechnologies (THTX, Financial) continues to focus on the commercialization of innovative therapies to redefine standards of care. More information about the company is available on their official website and financial disclosures can be accessed via SEDAR+ and EDGAR platforms.
